miR-122在非酒精性脂肪肝病患者血清中的表达及其临床意义

 目的 探讨microRNA-122(miR-122)在非酒精性脂肪肝病(non-alcoholic fatty liver disease, NAFLD)患者血清中的表达及其临床意义。方法 采用荧光定量RT-PCR技术检测健康人、高脂血症患者、非酒精性单纯性脂肪肝(non-alcoholic simply fatty liver, NAFL)及非酒精性脂肪性肝炎(non-alcoholic steatohepatitis, NASH)患者血清中miR-122的表达。结果 各组miR-122的表达水平分别为5.94±1.21(2^-△△Ct), 5.99±1.03(2^-△△Ct), 8.67±0.72(2^-△△Ct), 10.55±0.83(2^-△△Ct)。高脂血症患者和健康人血清中miR-122的表达量差异无统计学意义(P＞0.05)。与前两组相比, NAFL和NASH患者血清中miR-122的表达明显逐渐升高, 差异有统计学意义(P<0.05)。结论 非酒精性脂肪肝病患者血清中miR-122的表达量明显升高, 提示miR-122参与了非酒精性脂肪肝的形成及进展过程, 可作为诊断和评估组织学病变严重性的一种新的生物学指标, 同时有望成为一个潜在的治疗靶点。

Expression of miR-122 in nonalcoholic fatty liver disease and its clinical significance

Objective To analyze the expression levels of serum microRNA-122 (miR-122) in non-alcoholic fatty liver disease (NAFLD) patients, and its clinical significance. Methods Patients with normal liver, hyperlipidemia, non-alcoholic simply fatty liver(NAFL), non-alcoholic steatohepatitis(NASH)were included in this study. Blood samples of the patients were collected for analysis. Real time quantitative PCR technique was used to measure the expression level of serum miR-122. Results The expression levels of serum miR-122 was 5.94±1.21(2^-△△Ct), 5.99±1.03(2^-△△Ct), 8.67±0.72(2^-△△Ct)and 10.55±0.83(2^-△△Ct), respectively. The difference in the expression level between normal liver and hyperlipidemia patients was not statistically significant. Comparing with normal liver and hyperlipidemia patients, miR-122 presented higher expressions in NAFL patients(P<0.05), especially in NASH patients. Conclusion miR-122 plays an important role in NAFLD development and has early diagnostic value for indicating NAFLD. It may also be a potential therapeutic target in NAFLD with significant clinical value.